References
- Siegal S. Benign paroxysmal peritonitis. Ann Intern Med. 1945;23:1–21
- Saito M, Nishikomori R, Kambe N. Familial Mediterranean fever: MEFV gene mutations and treatment. Nihon Rins Men Gakkai Kaishi. 2007;30(2):78–85
- Yonem O, Bayraktar Y. Secondary amyloidosis due to FMF. Hepatogastroenterology. 2007;54(76):1061–1065
- Onen F. Familial Mediterranean fever. Rheumatol Int. 2006;26:489–496
- Juhan-Vague I, Renucci JF, Grimaux M, et al. Thrombin activable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156–2161
- Santamaria A, Oliver A, Borrell M, et al. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke. 2003;34:2387–2391
- Lau HK, Segev A, Robert A. Thrombin-activatable fibrinolysis inhibitor (TAFI) a novel predictor of angiografic coronary restenosis. Thromb Hemost. 2003;90(6):1187–1191
- Aksu G, Ozturk C, Kavakli K, Genel F, Kutukculer N. Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever. Clin Rheumatol. 2007;26:366–370
- Sato T, Akatsu H. Pro-carboxypeptidase R is an cute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol. 2000;165:1053–1058
- Flick MJ, Du X, Witte DP, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest. 2004;113:1596–1606
- Gil W. Inflammo-coagulatory response, extrinsic pathway thrombin generation and a new theory of activated clotting time interpretation. Perfusion. 2001;16:27–35
- Malyszko J, Malyszko JS, Hryszko T, Mysliwiec M. Thrombin activable fibrinolysis inhibitor and markers of endothelial cell injury in dialyzed patients with dibetic nephropathy. Thromb Hemost. 2004;91:480–486
- Terekeci HM, Oktenli C, Ozgurtas T, et al. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF? J Rheumatol. 2008;35(10):2024–2029
- Touitou I. The spectrum of familial Mediterranean (FMF) mutations. Eur J Hum Genet. 2001;9:473–483
- Tunca M, Akar S, Onen F, et al. Turkish FMF Study Group: Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11
- Pras E, Langevitz P, Livneh A. Genotype–phenotype correlation in familial mediterranean fever (a preliminary report). In: Sohar E, Gafni J, Pras M, eds. Familial Mediterranean Fever. Tel Aviv: Freund Publishing House; 1997:260–264
- Dewalle M, Domingo C, Rozenbaum M, et al. Genotype–phenotype correlation in Jewish patients suffering from Familial Mediterranean Fever. Eur J Hum Genet. 1998;6:95–97
- Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with familial Mediterranean fever. J Rheumatol. 2003;30(1):185–190
- Albayrak F, Selcuk NY, Odabas AR, Cetinkaya R, Pirim I. Genotype–phenotype correlation in patients with familial Mediterranean fever in East Anatolia (Turkey). Genet Test Mol Biomarkers. 2010;14(3):325–328
- Tunca M, Kirkali G, Soyturk M, Akar S, Pepys MB, Hawkins PN. Acute phase response and evolution of familial Mediterranean fever. Lancet. 1999;353:1415
- Bakkaloglu A. Familial Mediterranean fever. Pediatric Nephrol. 2003;18:853–859